Neprilysin deficiency alters the Neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 44, Issue 4, 2015, Pages 1291-1302

  Hüttenrauch, Melanie ^a   Baches, Sandra ^b   Gerth, Janina ^a,c   Bayer, Thomas A ^a   Weggen, Sascha ^b   Wirths, Oliver ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

Alzheimer's disease; amyloid; A PP; endothelin converting enzyme; intraneuronal A ; neprilysin; transgenic mice; working memory

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; ENDOTHELIN CONVERTING ENZYME; MEMBRANE METALLOENDOPEPTIDASE; AMYLOID PRECURSOR PROTEIN; ASPARTIC PROTEINASE; ENDOTHELIN-CONVERTING ENZYME; GLIAL FIBRILLARY ACIDIC PROTEIN; MESSENGER RNA; METALLOPROTEINASE; PRESENILIN 1; PSEN1 PROTEIN, HUMAN;

5XFAD MOUSE; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BLOOD BRAIN BARRIER; BRAIN REGION; CONTROLLED STUDY; FEMALE; KNOCKOUT MOUSE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SENILE PLAQUE; SPATIAL MEMORY; WORKING MEMORY; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; C57BL MOUSE; COMPLICATION; DEFICIENCY; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MAZE TEST; MEMORY DISORDERS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BRAIN; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MAZE LEARNING; MEMORY DISORDERS; METALLOENDOPEPTIDASES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEPRILYSIN; PRESENILIN-1; RNA, MESSENGER;

EID: 84923315910     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-142463     Document Type: Article

References (36)

1. SaidoT, LeissringMA (2012) Proteolytic degradation of amyloid-protein. Cold Spring Harb Perspec Med 2, a006379.
2. Selkoe DJ (2001) Clearing the brain's amyloid cobwebs. Neuron 32, 177-180.
3. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC (2001) Metabolic regulation of brain Abeta by neprilysin. Science 292, 1550-1552.
4. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-AizawaY, Saido TC (2000) Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition. Nat Med 6, 143-150.
5. Zou L-B, Mouri A, Iwata N, Saido TC, Wang D, Wang M-W, Mizoguchi H, Noda Y, Nabeshima T (2006) Inhibition of neprilysin by infusion of thiorphan into the hippocampus causes an accumulation of amyloid and impairment of learning and memory. J Pharmacol Exp Ther 317, 334-340.
6. Huang SM, Mouri A, Kokubo H, Nakajima R, Suemoto T, Higuchi M, Staufenbiel M, NodaY, Yamaguchi H, Nabeshima T, Saido TC, Iwata N (2006) Neprilysin-sensitive synapseassociated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J Biol Chem 281, 17941-17951.
7. Mohajeri MH, Wolfer DP (2009) Neprilysin deficiencydependent impairment of cognitive functions in a mouse model of amyloidosis. Neurochem Res 34, 717-726.
8. Iijima-Ando K, Hearn SA, Granger L, Shenton C, Gatt A, Chiang HC, Hakker I, Zhong Y, Iijima K (2008) Overexpression of neprilysin reduces alzheimer amyloid-beta42 (Abeta42)-induced neuron loss and intraneuronal Abeta42 deposits but causes a reduction in cAMP-responsive elementbinding protein-mediated transcription, age-dependent axon pathology, and premature death in Drosophila. J Biol Chem 283, 19066-19076.
9. Meilandt WJ, Cisse M, Ho K, Wu T, Esposito LA, Scearce-Levie K, Cheng IH, Yu G-Q, Mucke L (2009) Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic A oligomers and associated cognitive deficits in human Amyloid precursor protein transgenic mice. J Neurosci 29, 1977-1986.
10. Poirier R, Wolfer DP, Welzl H, Tracy J, Galsworthy MJ, Nitsch RM, MohajeriMH (2006) Neuronal neprilysin overexpression is associated with attenuation of A-related spatial memory deficit. Neurobiol Dis 24, 475-483.
11. Iwata N, Sekiguchi M, Hattori Y, Takahashi A, Asai M, Ji B, Higuchi M, Staufenbiel M, Muramatsu S-I, Saido TC (2013) Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Sci Rep 3, 1472.
12. Spencer B, Marr R, Rockenstein E, Crews L, Adame A, Potkar R, Patrick C, Gage F, Verma I, Masliah E (2008) Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice. BMC Neurosci 9, 109.
13. Hemming ML, Patterson M, Reske-Nielsen C, Lin L, Isacson O, Selkoe DJ (2007) Reducing amyloid plaque burden via ex vivo gene delivery of an A-degrading protease: A novel therapeutic approach to Alzheimer disease. PLoS Med 4, e262.
14. El-Amouri SS, Zhu H, Yu J, Marr R, Verma IM, Kindy MS (2008) Neprilysin: An enzyme candidate to slow the progression of Alzheimer's disease. Am J Pathol 172, 1342-1354.
15. Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM (2005) Age-and region-dependent alterations in A-degrading enzymes: Implications for A-induced disorders. Neurobiol Aging 26, 645-654.
16. Yasojima K, Akiyama H, McGeer EG, McGeer PL (2001) Reduced neprilysin in high plaque areas of Alzheimer brain:A possible relationship to deficient degradation of beta-amyloid peptide. Neurosci Lett 297, 97-100.
17. Devi L, Ohno M (2013) Mechanisms that lessen benefits of beta-secretase reduction in a mouse model of Alzheimer's disease. Transl Psychiatry 3, e284.
18. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. J Neurosci 26, 10129-10140.
19. Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O. (2012) Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Abeta aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol Aging 33, 196.e129-196.e140.
20. Lu B, Gerard NP, Kolakowski LF Jr, Bozza M, Zurakowski D, Finco O, Carroll MC, Gerard C (1995) Neutral endopeptidase modulation of septic shock. J Exp Med 181, 2271-2275.
21. Wirths O, Breyhan H, Schafer S, Roth C, Bayer TA (2008) Deficits in working memory and motor performance in the APP/PS1ki mouse model for Alzheimer's disease. Neurobiol Aging 29, 891-901.
22. Wirths O, Multhaup G, Czech C, Feldmann N, Blanchard V, Tremp G, Beyreuther K, Pradier L, Bayer TA (2002) Intraneuronal APP/A beta trafficking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice. Brain Pathol 12, 275-286.
23. Christensen DZ, Kraus SL, Flohr A, Cotel MC, Wirths O, Bayer TA (2008) Transient intraneuronal Abeta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice. Acta Neuropathol 116, 647-655.
24. Saul A, Sprenger F, Bayer TA, Wirths O (2013) Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer's disease. Neurobiol Aging 34, 2564-2573.
25. Levine H (1993) Thioflavine T interaction with synthetic Alzheimer's disease-amyloid peptides: Detection of amyloid aggregation in solution. Protein Sci 2, 404-410.
26. Breyhan H, Wirths O, Duan K, Marcello A, Rettig J, Bayer TA (2009) APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy. Acta Neuropathol 117, 677-685.
27. Hahn S, Bruning T, Ness J, Czirr E, Baches S, Gijsen H, Korth C, Pietrzik CU, Bulic B, Weggen S (2011) Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to gamma-secretase modulators regardless of their potency and structure. J Neurochem 116, 385-395.
28. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) method. Methods 25, 402-408.
29. Hillmann A, Hahn S, Schilling S, Hoffmann T, Demuth HU, Bulic B, Schneider-Axmann T, Bayer TA, Weggen S, Wirths O. (2012) No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease. Neurobiol Aging 33, 839.e39-839.e50.
30. FarrisW, Schütz SG, Cirrito JR, Shankar GM, Sun X, George A, Leissring MA, Walsh DM, QiuWQ, Holtzman DM, Selkoe DJ (2007) Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol 171, 241-251.
31. Fukami S, Watanabe K, Iwata N, Haraoka J, Lu B, Gerard NP, Gerard C, Fraser P, Westaway D, St George-Hyslop P, Saido TC (2002) Abeta-degrading endopeptidase, neprilysin, in mouse brain: Synaptic and axonal localization inversely correlating with Abeta pathology. Neurosci Res 43, 39-56.
32. Eckman EA, Eckman CB (2005) Abeta-degrading enzymes: Modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem Soc Trans 33, 1101-1105.
33. Vepsäläinen S, Hiltunen M, Helisalmi S, Wang J, van Groen T, Tanila H, Soininen H (2008) Increased expression of A degrading enzyme IDE in the cortex of transgenic mice with Alzheimer's disease-like neuropathology. Neurosci Lett 438, 216-220.
34. Eckman EA, Reed DK, Eckman CB (2001) Degradation of the Alzheimer's amyloid-peptide by endothelin-converting enzyme. J Biol Chem 276, 24540-24548.
35. Pacheco-Quinto J, Eckman EA (2013) Endothelin-converting enzymes degrade intracellular-Amyloid produced within the endosomal/lysosomal pathway and autophagosomes. J Biol Chem 288, 5606-5615.
36. Pacheco-Quinto J, Herdt A, Eckman CB, Eckman EA (2013) Endothelin-converting enzymes and related metalloproteases in Alzheimer's disease. J Alzheimers Dis 33 (Suppl 1), S101-S110.